• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

BCL2基因分型与前列腺癌生存率

BCL2 genotypes and prostate cancer survival.

作者信息

Renner Wilfried, Langsenlehner Uwe, Krenn-Pilko Sabine, Eder Petra, Langsenlehner Tanja

机构信息

Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, 8036, Graz, Austria.

Division of Internal Medicine, GKK Outpatient Department, Graz, Austria.

出版信息

Strahlenther Onkol. 2017 Jun;193(6):466-471. doi: 10.1007/s00066-017-1126-9. Epub 2017 Apr 10.

DOI:10.1007/s00066-017-1126-9
PMID:28396899
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5438415/
Abstract

PURPOSE

The antiapoptotic B‑cell lymphoma 2 (BCL2) gene is a key player in cancer development and progression. A functional single-nucleotide polymorphism (c.-938C>A, rs2279115) in the inhibitory P2 BCL2 gene promoter has been associated with clinical outcomes in various types of cancer. Aim of the present study was to analyze the role of BCL2-938C>A genotypes in prostate cancer mortality.

METHODS

The association between BCL2-938C>A (rs2279115) genotypes and prostate cancer outcome was studied within the prospective PROCAGENE study comprising 702 prostate cancer patients.

RESULTS

During a median follow-up time of 92 months, 120 (17.1%) patients died. A univariate Cox regression model showed a significant association of the CC genotype with reduced cancer-specific survival (CSS; hazard ratio, HR, 2.13, 95% confidence interval, CI, 1.10-4.12; p = 0.024) and overall survival (OS; HR 2.34, 95% CI 1.58-3.47; p < 0.001). In a multivariate Cox regression model including age at diagnosis, risk group, and androgen deprivation therapy, the CC genotype remained a significant predictor of poor CSS (HR 2.05, 95% CI 1.05-3.99; p = 0.034) and OS (HR 2.25, 95% CI 1.51-3.36; p < 0.001).

CONCLUSION

This study provides evidence that the homozygous BCL2-938 CC genotype is associated with OS and C in prostate cancer patients.

摘要

目的

抗凋亡的B细胞淋巴瘤2（BCL2）基因是癌症发生和发展的关键因素。抑制性P2 BCL2基因启动子中的功能性单核苷酸多态性（c.-938C>A，rs2279115）与多种癌症的临床结局相关。本研究的目的是分析BCL2-938C>A基因型在前列腺癌死亡率中的作用。

方法

在一项包含702例前列腺癌患者的前瞻性PROCAGENE研究中，研究BCL2-938C>A（rs2279115）基因型与前列腺癌结局之间的关联。

结果

在中位随访时间92个月期间，120例（17.1%）患者死亡。单变量Cox回归模型显示CC基因型与癌症特异性生存率（CSS）降低显著相关（风险比，HR，2.13，95%置信区间，CI，1.10 - 4.12；p = 0.024）以及总生存率（OS；HR 2.34，95% CI 1.58 - 3.47；p < 0.001）。在包含诊断年龄、风险组和雄激素剥夺治疗的多变量Cox回归模型中，CC基因型仍然是CSS差（HR 2.05，95% CI 1.05 - 3.99；p = 0.034）和OS差（HR 2.25，95% CI 1.51 - 3.36；p < 0.001）的显著预测因素。

结论

本研究提供了证据表明纯合的BCL2-938 CC基因型与前列腺癌患者的OS和CSS相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90d4/5438415/90416b7f63cf/66_2017_1126_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90d4/5438415/90416b7f63cf/66_2017_1126_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90d4/5438415/90416b7f63cf/66_2017_1126_Fig1_HTML.jpg

相似文献

1
BCL2 genotypes and prostate cancer survival.BCL2基因分型与前列腺癌生存率
Strahlenther Onkol. 2017 Jun;193(6):466-471. doi: 10.1007/s00066-017-1126-9. Epub 2017 Apr 10.
2
Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma.调控 BCL2 启动子多态性（-938C>A）与前列腺癌患者的不良预后相关。
Int J Cancer. 2011 Nov 15;129(10):2390-9. doi: 10.1002/ijc.25904. Epub 2011 Mar 25.
3
Influence of BCL2-938 C>A promoter polymorphism and BCL2 gene expression on the progression of breast cancer.BCL2-938 C>A启动子多态性和BCL2基因表达对乳腺癌进展的影响。
Tumour Biol. 2016 May;37(5):6905-12. doi: 10.1007/s13277-015-4554-0. Epub 2015 Dec 11.
4
Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer.高危前列腺癌调强放疗和雄激素剥夺治疗后致死原因。
Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):94-9. doi: 10.1016/j.ijrobp.2013.05.044.
5
Association of the CC genotype of the regulatory BCL2 promoter polymorphism (-938C>A) with better 2-year survival in patients with glioblastoma multiforme.调节 BCL2 启动子多态性（-938C>A）的 CC 基因型与多形性胶质母细胞瘤患者 2 年生存率的相关性。
J Neurosurg. 2011 Jun;114(6):1631-9. doi: 10.3171/2010.12.JNS10478. Epub 2011 Jan 21.
6
The AA genotype of the regulatory BCL2 promoter polymorphism ( 938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients.调控性BCL2启动子多态性（938C>A）的AA基因型与淋巴结阴性浸润性乳腺癌患者的良好预后相关。
Clin Cancer Res. 2007 Oct 1;13(19):5790-7. doi: 10.1158/1078-0432.CCR-06-2673.
7
Significant impact of biochemical recurrence on overall mortality in patients with high-risk prostate cancer after carbon-ion radiotherapy combined with androgen deprivation therapy.碳离子放疗联合雄激素剥夺治疗后，生化复发对高危前列腺癌患者总死亡率有显著影响。
Cancer. 2016 Oct 15;122(20):3225-3231. doi: 10.1002/cncr.30050. Epub 2016 Jun 28.
8
Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.短期雄激素剥夺疗法可改善接受调强放疗的中危前列腺癌患者的前列腺癌特异性死亡率。
Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1012-7. doi: 10.1016/j.ijrobp.2012.07.2374. Epub 2012 Sep 14.
9
Polymorphisms of BCL2 and BAX Genes Associate with Outcomes in Advanced Non-small cell lung cancer Patients treated with platinum-based Chemotherapy.BCL2和BAX基因多态性与接受铂类化疗的晚期非小细胞肺癌患者的预后相关。
Sci Rep. 2015 Dec 10;5:17766. doi: 10.1038/srep17766.
10
The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy.在接受剂量递增放疗的患者中，阳性活检核心的百分比提高了对前列腺癌特异性死亡的预测。
Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):e135-42. doi: 10.1016/j.ijrobp.2011.01.007. Epub 2011 Feb 23.

引用本文的文献

1
Association Aamong Ppolymorphisms in the Aapoptosis-Rrelated NKX3-1, Caspase-3, Caspase-9, and BCL-2 Genes and Prostate Cancer Susceptibility From 9706 Cases and 12,567 Controls.来自9706例病例和12567例对照的凋亡相关NKX3-1、半胱天冬酶-3、半胱天冬酶-9和BCL-2基因多态性与前列腺癌易感性的关联。
Cancer Rep (Hoboken). 2025 May;8(5):e70206. doi: 10.1002/cnr2.70206.
2
Prognostic Values of Gene Copy Number Alterations in Prostate Cancer.前列腺癌中基因拷贝数改变的预后价值。
Genes (Basel). 2023 Apr 22;14(5):956. doi: 10.3390/genes14050956.
3
The role of FASL, BCL-2 and BAX polymorphisms in brazilian patients with prostate cancer and benign prostatic hyperplasia.

本文引用的文献

1
Micronutrients in Oncological Intervention.肿瘤干预中的微量营养素
Nutrients. 2016 Mar 12;8(3):163. doi: 10.3390/nu8030163.
2
Vitamin D and prostate cancer prognosis: a Mendelian randomization study.维生素D与前列腺癌预后：一项孟德尔随机化研究
World J Urol. 2016 Apr;34(4):607-11. doi: 10.1007/s00345-015-1646-9. Epub 2015 Jul 25.
3
Association between SNPs in defined functional pathways and risk of early or late toxicity as well as individual radiosensitivity.特定功能通路中的单核苷酸多态性与早发性或迟发性毒性风险以及个体放射敏感性之间的关联。
FASL、BCL-2和BAX基因多态性在巴西前列腺癌和良性前列腺增生患者中的作用。
Mol Biol Rep. 2022 Oct;49(10):9445-9451. doi: 10.1007/s11033-022-07805-3. Epub 2022 Aug 21.
4
Identification of prognostic biomarkers related to the tumor microenvironment in thyroid carcinoma.鉴定甲状腺癌中与肿瘤微环境相关的预后生物标志物。
Sci Rep. 2021 Aug 10;11(1):16239. doi: 10.1038/s41598-021-90538-3.
5
microRNA Expression Profiling in Young Prostate Cancer Patients.年轻前列腺癌患者的微小RNA表达谱分析
J Cancer. 2020 Apr 7;11(14):4106-4114. doi: 10.7150/jca.37842. eCollection 2020.
6
rs4143815-, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy.rs4143815-，一种新的潜在免疫遗传生物标志物，可预测局部晚期前列腺癌放疗后生化复发。
Int J Mol Sci. 2019 Apr 27;20(9):2082. doi: 10.3390/ijms20092082.
7
Ophiopogonin D', a Natural Product From , Induces and RIPK1-Dependent and Caspase-Independent Apoptotic Death in Androgen-Independent Human Prostate Cancer Cells.麦冬皂苷D'，一种来自[具体来源未给出]的天然产物，在雄激素非依赖性人前列腺癌细胞中诱导坏死性凋亡和RIPK1依赖性及半胱天冬酶非依赖性凋亡性死亡。
Front Pharmacol. 2018 Apr 30;9:432. doi: 10.3389/fphar.2018.00432. eCollection 2018.
Strahlenther Onkol. 2015 Jan;191(1):59-66. doi: 10.1007/s00066-014-0741-y. Epub 2014 Aug 26.
4
Association of genetic variants in VEGF-A with clinical recurrence in prostate cancer patients treated with definitive radiotherapy.血管内皮生长因子 A 基因变异与接受根治性放疗的前列腺癌患者临床复发的相关性。
Strahlenther Onkol. 2014 Apr;190(4):364-9. doi: 10.1007/s00066-013-0503-2. Epub 2014 Jan 18.
5
Association of genetic variants in apoptosis genes FAS and FASL with radiation-induced late toxicity after prostate cancer radiotherapy.凋亡基因 FAS 和 FASL 中的遗传变异与前列腺癌放疗后晚期放射性毒性的关系。
Strahlenther Onkol. 2014 Mar;190(3):304-9. doi: 10.1007/s00066-013-0485-0. Epub 2014 Jan 16.
6
A BCL2 promoter polymorphism rs2279115 is not associated with BCL2 protein expression or patient survival in breast cancer patients.BCL2启动子多态性rs2279115与乳腺癌患者的BCL2蛋白表达或患者生存率无关。
Springerplus. 2012 Oct 23;1:38. doi: 10.1186/2193-1801-1-38. eCollection 2012.
7
The current role and limitations of surrogate endpoints in advanced prostate cancer.晚期前列腺癌中替代终点的作用和局限性。
Urol Oncol. 2014 Jan;32(1):28.e1-9. doi: 10.1016/j.urolonc.2012.10.001. Epub 2013 Feb 20.
8
Expression of Bcl-2 and Bax in advanced or metastatic prostate carcinoma.Bcl-2和Bax在晚期或转移性前列腺癌中的表达。
Urol J. 2012 Winter;9(1):381-8.
9
Impact of VEGF gene polymorphisms and haplotypes on radiation-induced late toxicity in prostate cancer patients.血管内皮生长因子基因多态性和单倍型对前列腺癌患者放射性迟发性毒性的影响。
Strahlenther Onkol. 2011 Dec;187(12):784-91. doi: 10.1007/s00066-011-1106-4. Epub 2011 Nov 17.
10
Association between single nucleotide polymorphisms in the gene for XRCC1 and radiation-induced late toxicity in prostate cancer patients.X 射线修复交叉互补基因 1 单核苷酸多态性与前列腺癌患者放射性迟发性毒性的关系。
Radiother Oncol. 2011 Mar;98(3):387-93. doi: 10.1016/j.radonc.2011.01.021. Epub 2011 Feb 21.